Apellis Pharmaceuticals announced that it has commenced its PEGASUS Phase 3 trial assessing the safety and efficacy of APL-2 in patients with paroxysmal nocturnal hemoglobinuria, or PNH, compared to eculizumab. The development was highlighted at the end of Apellis’ R&D Day, where the company provided important clinical updates on its PNH program. PNH is a rare, acquired, potentially life-threatening disease characterized by complement-mediated thrombosis and hemolytic anemia.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.